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Abstract 
Epigallocatechin gallate (EGCG), the main catechin of green tea, is described to have potential 
health benefits in several fields like oncology, neurology or cardiology. Currently, it is also under 
pre-clinical investigation as a potential therapeutic or preventive treatment during pregnancy 
against developmental adverse effects induced by toxic substances. However, the safety of 
EGCG during pregnancy is unclear due to its proven adverse effects on neural progenitor cells’ 
(NPCs) migration. As lately several strategies have arisen to generate new therapeutic agents 
derived from EGCG, we have used the rat ‘Neurosphere Assay’ to characterize and compare the 
effects of EGCG structurally related compounds and EGCG PEGylated PLGA nanoparticles on a 
neurodevelopmental key event: NPCs migration. Compounds structurally-related to EGCG 
induce the same pattern of NPCs migration alterations (decreased migration distance, 
decreased formation of migration corona, chaotic orientation of cellular processes and 
decreased migration of neurons at higher concentrations). The potency of the compounds does 
not depend on the number of galloyl groups, and small structure variations can imply large 
potency differences. Due to their lower toxicity observed in vitro in NPCs, 4,4’-bis[(3,4,5-
trihydroxybenzoyl)oxy]-1,1’-biphenyl and EGCG PEGylated PLGA nanoparticles are suggested as 
potential future therapeutic or preventive alternatives to EGCG during prenatal period. 
 




Abbreviations: CEEA: Ethic Committee for Animal Experimentation; cMINC: circular migration 
inhibition of neural crest cells; CTB: cellTiter-Blue Reagent; DMEM: Dulbecco’s modified Eagle 
médium; DMSO: dimethyl sulfoxide; DNT: developmental neurotoxicity; EC50: 50% effective 
concentrations; EE: encapsulation efficiency; EGC: epigallocatechin; EGCG: epigallocatechin 
gallate; EGF: epidermal growth factor; FASN: Fatty Acid Synthase; FGF: fibroblast growth factor; 
G37: 1,4-bis[(3,4,5-trihydroxybenzoyl)oxy]naphthalene; G56: 4,4’-bis[(3,4,5-
trihydroxybenzoyl)oxy]-1,1’-biphenyl; M1: 4-hydroxy-2-naphthyl 3,4,5-trihydroxybenzoate; M2: 
3-hydroxy-1-naphthyl 3,4,5-trihydroxybenzoate; Nano-EGCG: EGCG PEGylated-PLGA 
nanoparticles; NPCs: neural progenitor cells; PBS: phosphate buffered saline; PDL: poly-D-lysine; 
PEG: polyethylene glycol; PEGylated-PLGA nanoparticles: polyethylene glicosylated poly (lactic-
co-glycolic acid); PFA: paraformaldehyde; PI: polydispersity index; PLGA: poly (lactic-co-glycolic 
acid); PLGA-PEG: poly (lactic-co-glycolic acid)-polyethylene glicol; PND1: postnatal day 1; Zav: 
average particle size; ZP: zeta potential.  
1 Introduction 
Efforts towards improving nutritional status of pregnant women require the involvement of a 
wide range of specialists, among them toxicologists, as efficacy testing of nutritional 
supplementation should always be accompanied of safety evaluations. Several national and 
multinational studies report on the intake of herbal-based supplements during pregnancy with 
high variation on the reported percentages (reviewed by Barenys et al., 2017b) and describe 
that ‘health promotion’ is one of the ten most commonly reported reasons among pregnant 
women for using herbal-based supplements (Kennedy et al., 2013). As these substances are not 
subject to classical risk assessment evaluations, their general toxicities might be known, but 
there is a lack of information on specific toxicities concerning subtle endpoints like 
developmental neurotoxicity (DNT) (Barenys et al., 2017b). 
Epigallocatechin gallate (EGCG) is the most abundant catechin in green tea (Rothwell et al., 
2013). It is present in herbal-based food supplements which can be easily purchased online, in 
food shops or in supermarkets without the advice of health professionals. It has been described 
to have several potential health benefits (Hollman et al., 1999; Singh et al., 2011; Yang et al., 
2009) driven by its actions on numerous cellular targets involved in cell proliferation, adhesion, 
and migration ((Mineva et al., 2013; Shankar et al., 2008; Singh et al., 2011; Suzuki and Isemura, 
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2001), but these cellular processes are also essential for correct brain development (Holmes and 
McCabe, 2001), suggesting a hazardous potential for EGCG on neurodevelopment. 
In a previous study using human and rat neurospheres we have shown that EGCG inhibits 
adhesion and migration of neural progenitor cells (NPCs) and that at higher concentrations it 
also produces a reduction of the number of migrating young neurons in vitro, without affecting 
NPC proliferation (Barenys et al., 2017). An independent research group has recently 
reproduced these migration alteration effects in a different test model (cMINC) showing that 
EGCG also inhibits human neural crest cells migration in vitro (Nyffeler et al., 2017). Besides 
being a freely-available food-supplement, EGCG is also intensively studied at a preclinical level 
as a potential prenatal treatment to decrease developmental adverse effects induced by toxic 
substances, i.e. prevention of the neurodevelopmental adverse effects related to the fetal 
alcohol syndrome (Long et al., 2010; Tiwari et al., 2010), or adverse outcomes related with 
genetic diseases like cardiac hypertrophy and short-term memory deficits associated with 
Williams-Beuren syndrome (Ortiz-Romero et al., 2018) and reduction of craniofacial features 
associated with Down syndrome (McElyea et al., 2016).  
Even if EGCG stimulates an elevated interest for therapies in adults or during prenatal 
development, it displays poor bioavailability and limited stability under physiological conditions 
(Krupkova et al., 2016; Puig et al., 2009; Turrado et al., 2012), therefore in the last years several 
strategies have arisen to generate new therapeutical agents derived from EGCG to overcome 
these limitations: e.g. the use of polyethylene glycosylated poly (lactic-co-glycolic-acid) 
(PEGylated-PLGA) nanoparticles to encapsulate EGCG or the synthesis of EGCG analogues. Here 
we tested such EGCG alternatives in the ‘Neurosphere Assay’ to assess their potency to disturb 
(1) NPC migration distance (2) the formation of the migration corona (3) cellular process 
orientation angle, and (4) neuronal migration. In our study we included the original compound 
EGCG, EGCG PEGylated-PLGA nanoparticles (Nano-EGCG), the polyphenolic compounds G37 and 
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G56 with two galloyl units and a naphtyl or a biphenyl moiety, respectively, and M1 and M2 with 
one galloyl group (Figure 1). The inclusion of the latter was motivated by the results in our 
previous study where we observed that the natural catechin with only one galloyl group 
epigallocatechin (EGC, CAS: 970-74-1) disturbed the adhesion of NPCs less potently than EGCG 
(Barenys et al., 2017a). These five compounds: Nano-EGCG, G37, G56, M1, and M2, have already 
been tested for some beneficial effects related with, for example, their anticancer, anti-seizure, 
antibacterial and/or analgesic activity (Cano et al., 2018; Crous-Masó et al., 2018; Xifró et al., 
2015), yet their potential to interfere with neurodevelopmental processes like migration needs 
evaluation before they are tested as prenatal therapies or prenatal nutritional supplements.  
 
2 Material and methods 
2.1 Reagents 
(−)-Epigallocatechin-3-gallate (EGCG, CAS 989-51-5, purity > 98 %) was purchased from TransMIT 
PlantMetaChem (Giessen, Germany). 4-Hydroxy-2-naphtyl 3,4,5-trihydroxybenzoate (M1), 3-
hydroxy-1-naphtyl 3,4,5-trihydroxybenzoate (M2), 1,4-bis[(3,4,5-
trihidroxybenzol)oxy]naphthalene (G37) and 4,4'-bis[(3,4,5-trihidroxybenzol)oxy]-1,1'-biphenyl  
(G56) were synthesized as detailed by Crous-Masó et al., (2018) by the LIPPSO group at the 
University of Girona at a purity >90%. Stock solutions of EGCG and its four derivatives were 






 Poly (lactic-co-glycolic acid)-polyethylene glycol (PLGA-PEG) 5% was purchased from Evonik Co. 
(Evonik Co., Birmingham, USA). 1.5 mg/mL EGCG loaded PEGylated-PLGA nanoparticles were 
prepared at the laboratory of the ‘Nanostructured systems for controlled drug delivery’ research 
group as described in Cano et al., (2018). Briefly, the formulation with 1.5 mg/ml of EGCG, 14 
mg/ml of PLGA-PEG and Tween-®80 1.5% led to a monodisperse population (polydispersity 
index: PI < 0.1) of particles with an average particle size (Zav) of 168.5 ± 9.9 nm and an 
encapsulation efficiency (EE) higher than 95%. The formulation showed a zeta potential (ZP) 
value (-23.3 ± 5.3 mV). As the nanocarrier was formulated by the double emulsion method using 
Tween®80 as surfactant, working solutions of Nano-EGCG were prepared at a final 
concentration of 0.1% Tween®80.  
2.2 Ethics Statement 
The acquisition of brain tissue for preparation of neurospheres was approved by the Ethic 
Committee for Animal Experimentation of the University of Barcelona (CEEA) with license 
number OB 341/17. 
2.3 Proliferating cell culture establishment and maintenance 
See Figure 2 for a graphical representation of the experimental approach. Rat neural progenitor 
cells (NPCs) were isolated from whole brain of two postnatal day 1 (PND1) pups as previously 
described in Baumann et al., (2014). NPCs were cultivated as a floating culture in a humidified 
incubator at 37 °C and 5 % CO2 in B27-proliferation medium [Dulbecco’s modified Eagle medium 
(DMEM) and Hams F12 (3:1) with B27-supplement (Invitrogen GmBH, Karlsruhe, Germany), 20 
ng/mL Epidermal growth factor (EGF, Biosource, Karlsruhe, Germany), 10 ng/mL recombinant 
rat fibroblast growth factor (rrFGF, R&D Systems, Wiesbaden-Nordenstadt, Germany), 100 U/mL 
penicillin and 100 µg/mL streptomycin (PAN-Biotech)]. Every 2-3 days half of the medium was 
replaced with fresh B27-proliferation medium. As soon as neurospheres reached a certain size 
of 0.5-0.6 mm in diameter they were passaged mechanically with a tissue chopper (McIllwain) 
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to maintain their proliferative character. NPCs were chopped 3-4 days before plating on a poly-
D-lysine/laminin-coated surface in an 8-chamber slide to perform the differentiation assay as 
described below. 
2.4 Differentiation conditions and chemical exposure 
Studies of migration and differentiation were performed under differentiation conditions as 
described elsewhere (Baumann et al., 2014). Briefly, NPCs were plated onto a coated surface of 
poly-D-lysine (PDL; 0.1 mg/mL, Sigma Aldrich) and laminin (5 µg/mL, Sigma Aldrich) in an 8-
chamber slide filled with N2 differentiation medium [Dulbecco’s modified Eagle medium 
(DMEM) and Hams F12 (3:1) supplemented with N2 (Invitrogen GmBH, Karlsruhe, Germany), 
100 U/mL penicillin, and 100 µg/mL streptomycin (PAN-Biotech) in absence of the growth 
factors EGF and FGF]. 3-4 days after chopping five neurospheres of diameter 0.3 mm were 
placed on the surface of each chamber and exposed for 24 h to EGCG, Nano-EGCG, G37, G56, 
M1 or M2 at increasing concentrations (1, 5 and 10 µM) at 37°C in a humidified 5 % CO2 
incubator. Solvent controls were plated containing the same solvent concentrations then the 
tested compounds: 0.01% DMSO as solvent control for EGCG, G37, G56, M1 and M2 and 0.1% 
Tween®80 as solvent control for Nano-EGCG. EGF (20 ng/mL) was used as a positive control, 
since this concentration significantly increases migration and inhibits neuronal differentiation 
(Schmuck et al., 2017). Three to four independent experiments were performed for every 
endpoint and treatment. 
2.5 Migration  
All migration experiments were performed under differential conditions and were analyzed 
after an exposure time of 24 h. To evaluate the individual endpoints the whole migration area 
of each neurosphere was visualized using a high performance phase-contrast microscope (Nikon 




2.5.1 Migration distance  
The radial migration distance of each neurosphere was measured as described in Baumann et 
al., (2014) and Moors et al., (2007).  Briefly, the radius in four perpendicular angles from the 
edge of the neurosphere core to the furthest migrated cells was measured by using the ImageJ 
software. Subsequently the mean of the four radii was calculated to obtain the migration 
distance of each sphere.  
2.5.2 Corona of migrating cells   
The corona of migrating cells around the sphere core was calculated by manual measurement 
of the angles of the area covered with cells of the total corona around a sphere core (360°). The 
sum of all angles around the neurospheres covered by cells was calculated. 
2.5.3 Orientation angle measurement  
NPCs migrate in a specific orientation angle within the migration area which was manually 
analyzed in two frames (406.5 µm x 284.8 µm) per neurosphere. This orientation angle was 
measured in respect to the perpendicular direction from the sphere core for approximately 300 
cell processes per concentration and experiment and subsequently plotted in a color-coded 
polar plot using MatLab R2017b version.  
2.6 Viability testing 
Viability was assessed directly after capturing pictures for the migration assay (24h after 
exposure) by means of Alamar Blue Assay using the CellTiter-Blue Reagent (CTB) (Promega, 
Mannheim, Germany) as described in Baumann et al., (2014). 
2.7 Immunocytochemistry 
After 24h of exposure and subsequently viability testing cells were fixed overnight in 4 % 
paraformaldehyde (PFA) at 4 °C. On the following day cells were washed with 1x Phosphate 
Buffered Saline (PBS) and stored in PBS at 4 °C until immunofluorescence staining was 
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performed. To stain the cell nuclei and differentiated neurons within the migration area, 
neurospheres were incubated for 1h at 37 °C with 10 % goat serum and rabbit-anti-β(III)-tubulin 
first antibody (1:200; Sigma-Aldrich) in 1x Phosphate buffered saline with 0.1% (v/v) Triton-X 
100 (PBS-T) followed by 30 min incubation at 37 °C with 2 % goat serum, 1 % Hoechst 33258 
(Sigma-Aldrich) and anti-rabbit Alexa Fluor 546 secondary antibody (1:200; Sigma-Aldrich) in 1x 
PBS. Two images of the stained migrating area of each neurosphere were taken under a Nikon 
Eclipse TS100 fluorescence microscope. The number of Hoechst-positive cell nuclei was 
determined with the “Analyze Particle” command of ImageJ software (Rasband 1993-2007). βIII-
tubulin+ cells were quantified by manual counting in all images and expressed as percentage of 
the total number of cell nuclei within the two pictures corresponding to one neurosphere. 
2.8 Statistics  
Statistical analysis was performed with the Software GraphPad Prism, Version 7, by one-way 
ANOVA, followed by Bonferroni’s test in the one compound concentration-response 
experiments. Two-way ANOVA, followed by Bonferroni’s post hoc test was carried out to 
compare two compounds concentration-response curves. For each evaluated compound 50% 
effective concentrations (EC50) were calculated by applying a nonlinear sigmoidal dose-response 
inhibition curve fit with variable slope to the obtained data points (with constrains top= 100, 
bottom= 0). Two-way ANOVA, followed by Bonferroni’s post hoc test was also performed to 
determine the significance between angle-orientation variation and concentration. Student’s t-
test was used to compare the results between the two solvent controls and multiple student’s 
t-test was applied to determine the significance between angle-orientation variation and 
concentration between the two solvent controls. Significance threshold in all statistical analysis 





In a previous study, EGCG exposure for 24h disturbed migration of NPCs in both human and rat 
neurospheres (Barenys et al., 2017a). As there were no significant differences in sensitivity 
towards adverse EGCG effects between both species, we tested EGCG and five different related-
substances in only one model: the rat neurospheres. To follow the same approach of that study, 
we chose the same exposure period (24h), the same exposure concentration range (1 to 10 µM) 
and the same solvent control concentration (0.01% DMSO) in all cases except in the 
nanoparticulated formulation Nano-EGCG where the solvent control needed to be 0.1% 
Tween®80, the surfactant used to ensure the optimal physicochemical characteristics of the 
developed nanosystem (Cano et al., 2018). As 0.1% Tween®80 was never used as solvent control 
in the ‘Neurosphere Assay’ before, we present in Supplementary Figure 1 the comparison of the 
raw values obtained for all evaluated endpoints for 0.01% DMSO and 0.1% Tween®80 controls, 
showing no statistically significant differences for any migration- or neuronal differentiation-
related endpoint and a significant increase in cell viability was detected by means of Alamar-
Blue assay in the 0.1% Tween®80 group which indicates that this solvent concentration is not 
cytotoxic for NPCs in culture. 
 
The compounds selected to be included in this study were a nanoformulation of EGCG, and four 
EGCG structurally-related compounds including one (M1 and M2) or two (G37 and G56) galloyl 
groups (Figure 1). The tested compounds displayed different potencies in disturbing NPC 
migration distance after 24h of exposure. G37 and M2 produced significant decreases of 
migration distance at 5 µM, G56 and M1 caused this effect at the maximum concentration tested 
(10 µM), while Nano-EGCG did not significantly reduce the migration distance (Figure 3). G56, 
M1, M2 and Nano-EGCG displayed a significantly different concentration-response curve from 
the one of EGCG (Figure 3).  
10 
 
Besides decreasing the migration distance, we observed the previously described characteristic 
effect of EGCG disturbing the migration pattern by induction of gaps and branches in the 
migration area (Figure 3). This effect, which so far has only been reported after exposure to 
catechin related compounds or to a functional beta1-integrin antibody, can be assessed by 
measuring the angle of the corona surrounding each neurosphere core with presence of 
migrating cells, irrespective of the distance of migration from the neurosphere core as published 
before for EGCG evaluation (Barenys et al., 2017a) and previously described in a different 
developmental neurotoxicity test using stem cells and measuring the neural outgrowth 
surrounding embryoid bodies (Theunissen et al., 2011). When the angle of the corona 
surrounded by migrating cells was measured, the tested compounds displayed very similar 
potencies than in the migration distance assay: G37 and M2 significantly decreased the angle of 
corona at 5 µM, while G56 and M1 only presented significant effects at 10 µM and Nano-EGCG 
did not induce a significant reduction of the endpoint (Figure 3). Also in this case, when 
concentration-response curves of each compound were compared to the one of EGCG, all tested 
compounds displayed a significantly different curve profile than EGCG except G37 (Figure 3).    
To better compare the potencies of the effects among all compounds, 50% effective 
concentrations (EC50) were calculated for the two previously presented endpoints as well as for 
viability results by applying a nonlinear sigmoidal dose response curve fit to the obtained data 
points (Figure 4). EC50 values were above the tested concentrations for all endpoints for G56 and 
Nano-EGCG. For M1, EC50 values were also above the tested concentrations for all endpoints 
except for migration where it was 8.61 µM. In contrast, G37 presented EC50 values of the same 
magnitude than EGCG while M2 displayed approximately two times higher EC50 values for the 
endpoints migration distance and corona formation. Viability curves representing metabolic 
activity measured with the Alamar Blue Assay showed that EC50 values were not reached in any 
compound except for EGCG and G37. A very recent study shows that migration distance or 
pattern can define the magnitude of signal of viability assays like the  Alamar Blue Assay because 
11 
 
the metabolizing rate is related to number of cells in the migration area (Fritsche et al., 2018). 
Therefore it is not surprising that EGCG and G37, the two compounds with the strongest effect 
in migration distance and migration pattern are the only ones reaching an EC50 in the Alamar 
Blue Assay. In that study, to discard a direct cytotoxic effect of EGCG in NPCs a different assay 
not directly dependent on cell number was applied: FACS analyses identifying annexinV/PI 
positive cells clearly showed that EGCG does not cause cell death (Fritsche et al., 2018). 
 
A complementary approach to evaluate the effect of EGCG on the migration of NPCs is to 
measure the orientation angle of the cell migrating processes in a fixed area. As cells migrate 
radially from the neurosphere core, cellular processes of solvent control neurospheres were 
mainly oriented between 0° and ±30° angles toward the reference axis (for a schematic 
representation of the measurement method the reader is referred to Barenys et al., 2017a). In 
contrast, as previously observed, 24 h EGCG exposure caused a chaotic orientation of processes 
with a significantly increased percentage of cells between ±30° and ±60° angles. In this case, at 
higher concentrations, a significant increase in the percentage of cells oriented between ±60° 
and ±90° angles was also observed, while Nano-EGCG did not change the orientation of cell 
processes at any tested concentration (Figure 5).  
For the other four tested compounds, in all cases the disturbance effect induced was less potent 
than after exposure to EGCG, as no significant effects were observed at 1 µM and there was no 
significant increase in the percentage of cells oriented between ±60° and ±90° angles after 
exposure to any of the compounds tested. Again, when comparing among them four, the effect 
was more potent after exposure to G37 and M2 than after exposure to G56 or M1, which was 
not inducing significant effects until 10 µM. 
As in the ‘Neurosphere Assay’ the radial glial scaffold is normally used by young neurons to 
migrate away from the sphere core, we finally evaluated if the alterations in cell orientation had 
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an impact in the percentage of migrating neurons, as previously observed with EGCG in human 
NPC (Barenys et al., 2017a). Similar to previous results in human neurospheres, after 24 h of 
exposure, EGCG induced a significant reduction in the percentage of neurons in the migration 
area also of rat neurospheres only at the highest concentration tested (10 µM; Figure 6) (Barenys 
et al., 2017a). From all other compounds tested, only M2 induced a significant decrease in the 
percentage of neurons at concentrations even lower than EGCG (1 µM), while G37 and M1 
showed a trend to reduction without reaching statistical significance (ANOVA p value = 0.06 and 
0.07 respectively). Again, Nano-EGCG and G56 had no adverse effect on the endpoint studied at 
any concentration. 
4 Discussion 
The within-laboratory variability of the results obtained with the ‘Neurosphere Assay’ in control 
or exposed neurospheres has already been published in several articles performed by different 
operators over a long time (Baumann et al., 2016; Fritsche et al., 2005; Moors et al., 2009; 
Schmuck et al., 2017). In addition historical control values of the different endpoints of the 
neurosphere assay were summarized (Baumann et al., 2015). But so far, the transferability of 
the method in a second laboratory was not shown. In the present work, we reproduce the results 
previously published for solvent control (DMSO 0.01%) and EGCG exposed neurospheres in a 
different laboratory (University of Barcelona) of a different country (Spain), with different 
equipment and using neurospheres gained from a different rat strain (Sprague-Dawley). The 
values obtained in control culture conditions in this new lab fulfill the quality requirements 
previously published (Baumann et al., 2016, 2014) and EGCG exposure disturbed NPC migration 
by inducing the same pattern of alterations: significantly reduced migration distance, 
significantly decreased angle of corona with presence of migrating cells, significantly disturbed 
orientation of migrating cells’ processes, and at higher concentrations reduced neuronal 
migration. The transferability of results among laboratories is a requirement of the retrospective 
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validation process of new methods in toxicology described by Hartung et al., (2004), which 
outlines the path to evaluate the validity of a new test on the basis of a modular validation 
approach and which was already used for example to retrospectively validate the in vitro 
micronucleus test (Corvi et al., 2008). According to the recommendations on test readiness 
criteria for new approach methods in toxicology (Bal-Price et al., 2018) the present results 
contribute to prove the robustness of the ‘Neurosphere Assay’ (criteria 9c-interlab) and bring 
forward its readiness. 
The main aim of this study was to compare the effects of EGCG on NPC migration with the ones 
induced by the structurally related compounds G37, G56, M1, M2 and Nano-EGCG, developed 
as new therapeutical strategies. The overall evaluation of the endpoints shows a consistent 
pattern of different potencies of the tested compounds: 
EGCG ≈ G37 > M2 > M1 ≈ G56 > Nano-EGCG 
Several studies have shown that EGCG can bind to laminin (Peter et al., 2017; Suzuki and 
Isemura, 2001) and disturb the adhesion of cells to the extracellular matrix (Bracke et al., 1987; 
Chen et al., 2003; Suzuki and Isemura, 2001) finally leading to an altered cell migration pattern 
(Bal-Price et al., 2017; Barenys et al., 2017a; Nyffeler et al., 2017). The structural moieties 
inducing this altered cell migration seemed to be galloyl/pyrogallol groups because in a previous 
study, catechins lacking these residues did not disrupt cell adhesion (Barenys et al., 2017a). In 
that study we postulated that compounds with only one galloyl or pyrogallol moiety would 
disturb NPC migration less potently than compounds including two of them. With the results of 
the present work we can refute this hypothesis, as M2 with only one galloyl moiety disturbs 
migration more potently (EC50migration-M2= 3.06µM) than G56 with two (EC50migration-G56= not 
reached). The current results also indicate that variations in the main structure can cause large 
differences in migration disturbance potency as G37 and G56 include both two galloyl groups 
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but G37 with a naphthyl unit disturbs migration more potently than G56  with a biphenyl one 
(EC50migration-G37= 2.17µM << EC50migration-G56= not reached). 
Hence, the structural interplay between galloyl groups and other aromatic ring groups within 
the same molecule seems to determine laminin binding capacity that masks integrin binding 
sites. To unravel the precise structures necessary for exerting these effects, more compounds 
structurally related to EGCG need to be tested in this assay. 
To compare the EGCG-related compounds’ potencies at an in vivo relevant concentration-range 
all compounds were tested between 1 and 10 µM (reviewed by Barenys et al., 2017b). 
Concentrations of EGCG in human plasma within this range have already been described after 
EGCG supplements intake (Shanafelt et al., 2009; Ullmann et al., 2003), however, a 5 or 10 µM  
concentration would not be achievable in individuals with a non-supplemented diet (Skibola and 
Smith, 2000).  When tested at this range of concentrations, compounds G37 and M2 disturbed 
some endpoints with an EC50< 5µM. G56 and M1 significantly disturbed migration distance and 
the formation of the migration corona only at 10 µM and for G56 EC50 values were not reached 
within the tested concentrations. For these compounds, concentrations around 10 µM are not 
achieved in the developing brain in vivo, as pharmacokinetic studies in pregnant rats indicate 
that for example total EGCG is found at approximately eight times lower concentrations in the 
fetal brain than in maternal plasma (Chu et al., 2006). However, pharmacokinetic studies in 
pregnant animals with G37, G56, M1, M2 or Nano-EGCG have not been performed yet. In this 
sense, even if 10 µM EGCG already induce a total response in migration, and higher 
concentrations would exceed in vivo relevance, the addition of a 20 µM concentration for some 
of the other tested compounds would have strengthened the calculation of EC50 values. 
According to our results, M1 and G56 would seem good candidates to develop therapeutic or 
preventive strategies for pregnant women, however, M1 induces a non-significant decrease in 
migration of young neurons after 24h (p=0.07) which could be expected to become stronger 
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after longer exposures. As G56 does not induce any reduction in this endpoint either, G56 would 
seem a better alternative than M1. Other studies have shown that G56 is significantly more 
effective than EGCG in reducing thermal hyperalgesia in a chronic constriction nerve injury mice 
model, that it displays strongest inhibition of lipogenic enzyme fatty acid synthase (FASN) than 
EGCG and that compared to the control group it does not cause significant changes on body 
weight neither alterations in hepatic, renal or hematological function markers at daily doses of 
50 and 75 mg/Kg (Xifró et al., 2015). 
Furthermore, the nanoformulation of EGCG did not disturb any of the evaluated endpoints in 
this study (EC50s= not reached for any endpoint). It is expected that in this particular case EGCG 
presents a more sustained release to the medium than when neurospheres are exposed to the 
free drug as this is precisely one of the aims of nanoencapsulating a compound, to contribute to 
a slower delivery of the drug. This sustained delivery might be responsible of a decreased 
concentration in the medium and a decreased interaction of the compound with the cells of the 
sphere or with the extracellular matrix, and therefore be responsible of a decrease or in this 
case an avoidance of adverse effects. The fact that a different solvent control was used while 
testing Nano-EGCG (0.1% Tween®80) did not influence the outcome, as the results of this solvent 
control are comparable with the ones of the solvent control used for G37, G56, M1 and M2 
(0.01% DMSO; Supplementary Figure 1). This comparison also contributes to identify Tween®80 
as a usable solvent control in the ‘Neurosphere Assay’, which might be of relevance due to its 
common use to develop nanoparticulated systems. Based on our results, Nano-EGCG could also 
be a potentially useful alternative to EGCG for developmental therapies. Previously published 
studies showed that Nano-EGCG significantly reduced the number and the intensity of epileptic 
episodes in mice more than the administration of the free drug (Cano et al., 2018).  
Finally, it is important to remark that compounds containing galloyl moieties should be 
suspected to disturb the neurodevelopmental key event ‘NPC migration’, and therefore, 
16 
 
developmental neurotoxicity relevant evaluations should be included in the process of 
developing new medical drugs structurally-related with this family. 
In summary, we can conclude that several compounds structurally-related to EGCG that are 
designed as its new therapeutical alternatives, induce the same pattern of alterations in the 
migration of NPCs than EGCG and some of them do it with the same potency (G37). In general, 
the potency of the effects of these compounds does not necessarily depend on the number of 
galloyl groups present in the molecule. This study suggests G56 and Nano-EGCG as potential 
therapeutic or preventive alternatives to EGCG for the prenatal period but further 
comprehensive evaluations of the neurodevelopmental effects of these compounds are needed 
to confirm their safety. 
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Figures and Figure legends: 
 
 
Figure 1. Chemical structure of the tested compounds. EGCG (458.375 g/mol): epigallocatechin gallate; 
M1 (312.27 g/mol): 4-hydroxy-2-naphthyl 3,4,5-trihydroxybenzoate; M2 (312.27 g/mol): 3-hydroxy-1-
naphthyl 3,4,5-trihydroxybenzoate; EGCG PEGylated-PLGA Nanoparticles (Nano-EGCG); G37 (464.38 









Figure 2. Graphical representation of the experimental approach. Migration distance. Phase-contrast 
image of the whole migration area of a rat neurosphere after 24 h of culture on a PDL/laminin coated 
surface. Migration distance measurement in 4 perpendicular radii from the neurosphere edge to the 
furthest migrated cells is exemplified with 4 arrows. Migration corona. Phase-contrast image of the whole 
migration area of a rat neurosphere after 24 h of culture on a PDL/laminin coated surface. The angle of 
the corona with presence of migrating cells surrounding the neurosphere core is represented with an 
arrow. Orientation angle. Phase-contrast image of the right side of the migration area of a rat 
neurosphere after 24 h of culture on a PDL/laminin coated surface. Measurement of 20 orientation angles 
is represented with discontinuous arrows. Neuronal differentiation. Fluorescent microscope image of the 
upper part of the migration area of a rat neurosphere after 24 h of culture on a PDL/laminin coated 
surface, fixation and immunocytochemistry. Blue: nuclei staining (Hoechst), green: neuronal marker (βIII-








Figure 3. EGCG, Nano-EGCG and structurally related compounds display different potencies in 
disturbing NPC migration distances and the formation of the migration corona. Rat neurospheres were 
cultured for 24 h with increasing concentrations of EGCG, Nano-EGCG, G37, G56, M1 and M2. Migration 
distance (A) and the angle of the corona with presence of migrating cells surrounding the neurosphere 
core (B) were evaluated in five neurospheres/concentration in four independent experiments. Results are 
presented as mean ± SEM in % of respective solvent control (DMSO 0.01 % for EGCG, G37, G56, M1 and 
M2 or 0.1% Tween®80 for Nano-EGCG), and mean ± SEM angle values in degrees, respectively. *p < 0.05 
27 
 
versus respective solvent control by one-way ANOVA and Bonferroni test. #p<0.05 versus EGCG 
concentration-response curve by two-way ANOVA. C. Representative phase-contrast images of 
neurospheres exposed to 5 µM of each test compound for 24h showing part of their migration area with 
one of the measured distances indicated with an arrow. D. Representative phase-contrast images of 
neurospheres exposed to solvent control 0.01% DMSO, or 5 µM of all tested compounds for 24h showing 
the full migration area and the measured angles of corona with migrating cells around a sphere (In solvent 
control picture D, an arrow indicating the measured migration distance is also included for comparison 












Figure 4. EGCG structurally related compounds display different potencies in disturbing NPCs migration 
related endpoints. Rat neurospheres were cultured for 24 h with increasing concentrations of EGCG, 
Nano-EGCG, G37, G56, M1 and M2. Blue (viability), black (migration) and orange lines (angle of corona 
with migrating cells) represent the nonlinear sigmoidal dose response curve fitted to the data points of 
four independent experiments using GraphPad Prism v7. Data points represent the mean ± SEM in % of 
respective solvent control (DMSO 0.01 % for EGCG, G37, G56, M1 and M2 or 0.1% Tween®80 for Nano-








Figure 5. EGCG, Nano-EGCG and structurally related compounds display different effects on the 
orientation of migrating cells processes. Color-coded polar plot displaying the orientation of cellular 
processes in relation to the reference axis after exposure of rat neurospheres to increasing concentrations 
of EGCG, Nano-EGCG, G37, G56, M1 and M2 during 24 h. Blue: angles from −30 to 30°, yellow: angles from 
30° to 60° and −30° to −60°, red: angles from 60° to 90° and −60° to −90°. Results are expressed in 
percentage of the total angles measured (vertical axis represents percentage in logarithmic scale). Data 
representing 3 independent experiments, where the angle of 240 cell processes in average per 
concentration and experiment were measured. *p < 0.05 versus respective solvent control angle group by 
two-way ANOVA and Bonferroni analysis (EGCG, G37, G56, M1 and M2 solvent control: 0.01% DMSO; 


















Figure 6. EGCG structurally related compounds display different potencies in disturbing the migration 
of young neurons. A. Rat neurospheres were cultured for 24 h with increasing concentrations of EGCG, 
Nano-EGCG, G37, G56, M1 and M2. The number of βIII-tubulin+ cells was manually counted in two areas 
per neurosphere and five neurospheres per concentration in three independent experiments and divided 
by the total number of nuclei in the two areas. Results represent the mean ± SEM in % of respective 
solvent control (DMSO 0.01 % for EGCG, G37, G56, M1 and M2 or 0.1% Tween®80 for Nano-EGCG). *p < 
0.05 versus respective solvent control by one-way ANOVA and Bonferroni test. B. Representative pictures 
of neurospheres exposed to 10 µM of the tested compounds and their respective solvent controls. Blue: 










Supplementary Figure 1. Comparison of 0.01% DMSO and 0.1% Tween®80 as solvent control substances 
in the rat ‘Neurosphere Assay’. Rat neurospheres were cultured for 24 h with 0.01% DMSO or 0.1% 
Tween®80. All endpoints were evaluated in five neurospheres/concentration in three or four independent 
experiments. In A, B, C and E results are presented in box-and-whiskers representing minimum and 
maximum values in. D, color-coded polar plot displaying the orientation of cellular processes in relation 
to the reference axis. Blue: angles from −30 to 30°, yellow: angles from 30° to 60° and −30° to −60°, red: 
angles from 60° to 90° and −60° to −90°. Results are expressed in percentage of the total angles measured 
(vertical axis represents percentage in logarithmic scale). Data representing 3 independent experiments. 
*p < 0.05 versus respective solvent control by Student’s-t test.  
 
